Stock Price Quote

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE280.359.35 (+3.45 %)
PREV CLOSE ( ) 271.00
OPEN PRICE ( ) 275.30
BID PRICE (QTY) 280.35 (906)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 257539
TODAY'S LOW / HIGH ( )271.60 281.10
52 WK LOW / HIGH ( )217.5 307
NSE280.159 (+3.32 %)
PREV CLOSE( ) 271.15
OPEN PRICE ( ) 275.00
BID PRICE (QTY) 280.15 (14863)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10392195
TODAY'S LOW / HIGH( ) 271.30 281.00
52 WK LOW / HIGH ( )217.5 307.1
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

20Apr Biocon informs about disclosure
Biocon has informed about a notification as follows: ‘Biocon Limited has..
18Apr Biocon, Aster DM Healthcare and Suntec
Biocon has signed an exclusive licensing and supply agreement with Biomm..
18Apr Biocon signs licensing and supply agre
Biocon has signed an exclusive licensing and supply agreement with Biomm..
18Apr Biocon shines on signing licensing and
Biocon is currently trading at Rs. 270.20, up by 7.10 points or 2.70% fr..
12Apr Biocon informs about updates
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit24028484
Gross Profit 329 29712
Operating Profit 11982949
Net Sales 562819929

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)390.76
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95896.87
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89224.37
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26893.07
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91

Shareholding Pattern

MUTUAL FUNDS/UTI 8.57%
PROMOTERS 60.64%
FI/BANKS/INSURANCE 5.02%
NON-INSTITUTION 20.05%
GOVERNMENT 0%
FII 0%

About Biocon Ltd.

Biocon Ltd. was incorporated in the year 1978. Its today's share price is 280.35. Its current market capitalisation stands at Rs 33658.82 Cr. In the latest quarter, company has reported Gross Sales of Rs. 19929 Cr and Total Income of Rs.22670 Cr. The company's management includes Nicholas Robert Haggar, Rekha Mehrotra Menon, Mayank Verma, Peter John Bains, Naina Lal Kidwai, Bobby Kanubhai Parikh, Meleveetil Damodaran, Eric Vivek Mazumdar, Ravi Rasendra Mazumdar, Siddharth Mittal, Kiran Mazumdar-Shaw.

It is listed on the BSE with a BSE Code of 532523 , NSE with an NSE Symbol of BIOCON and ISIN of INE376G01013. It's Registered office is at 20th Km,Hosur Road,Electronic CityBengaluru-560100, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, SR Batliboi & Associates, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.